Enrich Biosystems Raises Over $10 Million to Advance High-Throughput Cell Analysis Platform
Enrich Biosystems Inc., a Branford, Connecticut–based life science tools company developing a microfluidics-free high-throughput cell imaging, analysis and retrieval platform, has steadily expanded its funding base since its founding in 2018, blending venture investment, debt financing and early ecosystem support. The company’s flagship platform, TROVO, is designed to accelerate discovery in cell therapy, immuno-oncology and precision medicine by enabling functional cell profiling and retrieval through streamlined workflows that address limitations in conventional screening technologies.
Since inception, Enrich has raised more than $10 million across multiple funding rounds, including equity investments, debt financings and support from accelerators and innovation programs. This cumulative funding reflects sustained investor and institutional confidence in the company’s technology and its potential to improve how researchers identify, analyze and recover rare and functionally relevant cells.
Enrich’s venture backing began with early seed-stage investments that supported the development and validation of its platform and initial commercialization activities. In May 2024, the company completed a seed-stage financing that raised capital in the low millions to further advance engineering, product refinement and customer engagement. The round included participation from Elm Street Ventures, a Connecticut-based early-stage venture capital firm with a focus on life sciences and technology companies, alongside additional undisclosed investors from the biotech and research tools ecosystem.
Before raising institutional venture capital, Enrich benefited from early-stage accelerator and innovation program support that helped shape its business model and technical roadmap. The company participated in programs such as BioTools Innovator, which provided mentorship, industry exposure and non-dilutive resources to help life science tools startups transition from concept to market-ready products. These early programs played a role in building operational momentum and visibility within the biotechnology community.
In addition to equity financing, Enrich has supplemented its capital structure with debt funding, securing multiple debt tranches to support ongoing operations and growth. Debt financings completed in May 2024 and again in November 2025 totaled more than $2 million, providing additional runway to scale research and development, expand sales and marketing efforts, and support customer deployments without further equity dilution.
According to industry data, Enrich Biosystems has worked with nine distinct investors over the course of its funding history. Beyond Elm Street Ventures, this investor base includes a mix of institutional backers, strategic supporters and individual investors aligned with life science tools, biotechnology innovation and high-growth research platforms. This diverse funding mix has enabled Enrich to pursue a long-term product strategy while remaining capital-efficient.
The company’s progress has also been reinforced by external recognition that has helped elevate its profile with investors and potential partners. In November 2024, Enrich’s TROVO platform was named Cell Sorting Product of the Year by BioTech Breakthrough, highlighting the platform’s technical differentiation and its relevance to modern cell therapy and immunology research workflows.
Leadership and governance have further strengthened Enrich’s ability to attract funding and industry attention. Board members such as Daniel Wagner and Christopher K. McLeod bring experience in biotechnology investment and company building, while advisor Jay Teich contributes expertise in technology commercialization and fundraising. Together, this group supports strategic decision-making as Enrich balances scientific innovation with commercial execution.
As Enrich Biosystems moves forward, its blended funding strategy — combining venture capital, debt financing, accelerator support and industry recognition — positions the company to continue scaling adoption of its TROVO platform. With continued backing from investors and partners, Enrich aims to accelerate biological discovery and enable more efficient development of next-generation cell-based therapies and precision medicine solutions.
